COMPUMED INC. CMPD overview

Techcyte , the world leader in AI-based cellular digital diagnostics, is pleased to announce a collaboration with CompuMed to enhance the digital manual review of available livers and kidneys for organ transplantation. As a leader in diagnostic telemedicine, CompuMed prides itself on providing remote pathology reads anywhere, at any time. To further its mission and better serve its partners in the donation and transplantation community, CompuMed has adopted the Techcyte digital reviewing...

LOS ANGELES, CA / ACCESSWIRE / August 12, 2022 / CompuMed, Inc. (OTC PINK:CMPD) ("CompuMed" or the "Company") is pleased to announce fiscal 2022 3rd quarter results: FISCAL 2022 THIRD QUARTER HIGHLIGHTS: Revenue in our third fiscal quarter rose 2.1% compared to the second quarter but declined 7.4% year-over year. We would remind investors that our year ago quarter was our highest revenue quarter ever, so it was a tough comparable this quarter. Recently we have been investing more resources and...

LOS ANGELES, CA / ACCESSWIRE / May 23, 2022 / CompuMed, Inc. (OTC PINK:CMPD), a leader in providing diagnostic telemedicine, announced today that the 1-for-25 reverse stock split previously approved by the Company's stockholders at the annual meeting of stockholders held on March 15, 2022, has gone effective. As a result of the reverse stock split, effective as of May 23, 2022, every twenty-five shares of issued and outstanding Company common stock will be automatically combined into one issued...

LOS ANGELES, CA / ACCESSWIRE / May 13, 2022 / CompuMed, Inc. (OTC PINK:CMPD) ("CompuMed" or the "Company") is pleased to announce fiscal 2022 2nd quarter results: FISCAL 2022 SECOND QUARTER: Revenue for the 2 nd quarter was $1.6 million compared to $1.63 million a year ago and $1.54 million in the fiscal 1 st quarter of 2022 (a decrease of 1.9% and an increase of 3.9% respectively). Operating income in the quarter was $53,000 compared to $160,000 a year ago and $121,000 in the fiscal 1 st...

LOS ANGELES, CA / ACCESSWIRE / April 20, 2022 / CompuMed, Inc. (OTC PINK:CMPD) , a leader in providing diagnostic telemedicine, announced in March 2022 the approval by its stockholders of a 25:1 reverse stock split. As previously disclosed, the Company is in the process of submitting the appropriate documents to FINRA and its transfer agent, ComputerShare, to effect the reverse stock split as quickly as possible, with an anticipated effective date in mid - May 2022; the Company will provide...

LOS ANGELES, CA / ACCESSWIRE / March 22, 2022 / CompuMed, Inc. (OTC PINK:CMPD), a leader in providing diagnostic telemedicine, is pleased to announce publicly the vote results from the shareholder meeting held March 15 th , 2022. Results: A total of 27,653,647 shares were voted at the meeting. This compares to total eligible voting shares of 42,291,070. Therefore a total of 65.4% of eligible shares were voted at the meeting. Lee Keddie received 98.0% of all votes cast in favor of his candidacy...

LOS ANGELES, CA / ACCESSWIRE / February 14, 2022 / CompuMed, Inc. (OTC PINK:CMPD) ("CompuMed" or the "Company") is pleased to announce fiscal 2022 1st quarter results: FISCAL 2022 FIRST QUARTER RESULTS Revenue for the 1 st quarter was $1.54 million compared to $1.47 million a year ago and $1.45 million in the fiscal 4 th quarter of 2021 (increases of 4.6% and 5.9% respectively). Operating income in the quarter was $121,000 compared to $108,000 a year ago and $495,000 in the fiscal 4 th quarter...

LOS ANGELES, CA / ACCESSWIRE / April 12, 2018 / CompuMed, Inc. (OTC PINK: CMPD), a leader in providing diagnostic telemedicine, announced today that it is redeeming the 8,400 outstanding shares of its Class A $3.50 Cumulative Convertible Preferred Stock and the 300 outstanding shares of its Class B $3.50 Convertible Preferred Stock. The Company today mailed redemption notices to holders of record of each of these two classes of preferred stock. If holders of record transferred shares to other...